CEO Chris Calhoun presents at Biotech Showcase 2013 on January 8, 2013

1. C Y TherapyI
Personalized Cell TOR
THE TRUSTED LEADER
IN CELL THERAPY
NASDAQ: CYTX 1

2. Safe Harbor Statement
This presentation contains certain ‘forward-looking statements’ about Cytori Therapeutics, Inc. All
statements, other than statements of historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate will or may occur in the future are forward-
looking statements. Such statements are based upon certain assumptions and assessments made by
our management in light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be appropriate.
The forward-looking statements included in this presentation involve known and unknown risks that
relate to Cytori’s future events or future financial performance and the actual results could differ
materially from those discussed in this presentation. Risks and uncertainties that may cause Cytori's
actual results to differ materially from those discussed in the presentation can be found in the "Risk
Factors" section of Cytori’s Form 10-K, Forms 10-Q and other filings with the United States Securities
and Exchange Commission. We would advise reading our most recent annual report on Form 10-K
and quarterly report on Form 10-Q filed with the United States Securities and Exchange Commission
for a more detailed description of these risks.
The forward-looking statements contained in this presentation represent Cytori’s estimates and
assumptions only as of the date of this presentation and Cytori undertakes no duty or obligation to
update or revise publicly any forward-looking statements contained in this presentation as a result of
new information, future events or changes in Cytori’s expectations.
2

3. Mission: Improve the quality & length of life
through innovative CELL THERAPY products
CYTORI CELL THERAPY 3

4. i. Business and Technology Overview
ii. Cardiovascular Pipeline
iii. Soft Tissue Pipeline
iv. Commercial
CYTORI CELL THERAPY

5. Cytori Cell Therapy
Your tissue is processed right
at the side of your bed
Fat (adipose) tissue Celution® System: Adipose-derived stem &
from minor liposuction point-of-care device regenerative cells (ADRCs)
5

6. Clinical Leadership
Thousands of patients around the world
have been treated
using their own (ADRC) cells
5 Company-Sponsored Trials
 3 Complete (2 cardiovascular, 1 Breast)
 2 Ongoing (2 cardiovascular)
40+ Investigator-Sponsored Studies
 Chronic burns, radiation wounds, fistula
repair, urinary incontinence, breast
reconstruction, PVD, heart failure, liver,
scleroderma, & others
ADRCs: becoming the “go to” source for Clinical Cell Therapy 6

7. Cytori Cell Therapy Development Pipeline
Preclinical Phase I/II Pivotal Full Market
Access
Private Pay/
Reimbursement
Refractory Heart
Failure
U.S.
Vascular Delivery Europe
Acute Myocardial
Infarction
Europe
BARDA (Burns) U.S.
Breast Recon &
Soft Tissue
Europe/AP
Independent App
Development
Europe/AP
7

8. 54 Worldwide Issued Patents; 75+ Pending
DEVICES DEVICES COSMETIC & RECONSTRUCTIVE CARDIOVASCULAR THERAPIES PIPELINE THERAPIES
CURRENT NEXT GENERATION SURGERY
US: (6) US: (1) US: (6) EUROPE: (2) US: (3)
CELUTION DEVICE (‘484) CELUTION & FUTURE CELUTION FOR MIXING ADRCS ADRCS FOR CARDIAC (‘382) OPPOSED CELUTION FOR BONE (‘043)
CELUTION DEVICE PLUS ADDITIVES (‘420) GENERATIONS (‘075) PLUS FAT (‘488) DEVICE FOR RESTORING BLOOD FLOW CELUTION OUTPUT PLUS
STEMSOURCE DEVICE (‘115) (‘575) OPPOSED
CELUTION OR NEXT GEN DEVICES PROSTHETIC
CELUTION DEVICE PLUS SENSORS FOR CHINA: (1) FOR SOFT TISSUE DEFECTS (‘684) FOR BONE RELATED
CLINICALLY SAFE OUTPUT (‘670)
AUSTRALIA: (1)
CELUTION & FUTURE ADRCS PLUS FAT PLUS ADDITIVES ADRCS FOR CARDIAC (‘858) DISORDERS (‘716)
BEDSIDE COMPREHENSIVE GENERATIONS (‘241) (‘795) ADRCS FOR WOUND
DEVICE (‘059)
ADRCS PLUS FAT (‘672) SINGAPORE: (1) HEALING (‘580)
CELUTION DEVICE CD31 POSITIVE CELLS
INDIA: (1) ADRCS PLUS FAT ADRCS FOR RESTORING BLOOD
(‘276) FLOW(‘309)
CELUTION WITH CENTRIFUGE COMPOSITION (‘121) EUROPE: (2)
OR FILTER (‘529) CURRENT CELUTION DEVICE + CELUTION FOR ACUTE
JAPAN: (2) CHINA: (1)
CELUTION DEVICE (‘952) FAT (‘947) TUBULAR NECROSIS (‘834)
ADRCS FOR RESTORING BLOOD FLOW
CELUTION FOR CLINICALLY SAFE OUTPUT AUSTRALIA: (1) (‘104) ADRCS FOR WOUND
(‘556) CELUTION WITH CENTRIFUGE JAPAN: (1) HEALING (‘833)
OR FILTER (‘937) CELUTION AND NEXT GEN DEVICES HONG KONG: (1)
KOREA: (3) FOR MIXING ADRCS PLUS FAT ADRCS FOR RESTORING BLOOD FLOW JAPAN: (3)
CELUTION DEVICE (‘995) SINGAPORE: (1) (‘041) (‘085) ADRCS FOR WOUND
STEMSOURCE DEVICE (‘812) CELUTION & FUTURE HEALING (‘699)
CELUTION DEVICE (‘139) GENERATIONS (‘683) KOREA: (3) RUSSIA: (1) CELUTION OUTPUT PLUS
CELUTION FOR RESTORING BLOOD FLOW
ADRCS PLUS FAT (‘454) PROSTHETIC
INDIA: (1) (‘924)
ISRAEL: (1) CELUTION OR NEXT GEN DEVICES FOR BONE RELATED
CELUTION DEVICE (‘706) CELUTION WITH CENTRIFUGE FOR SOFT TISSUE DEFECTS (‘508) DISORDERS (‘119)
SOUTH AFRICA: (1)
OR FILTER (‘800) ADRCS PLUS FAT METHOD ADRCS FOR CARDIAC (‘446) CELUTION FOR PERIPHERAL
AUSTRALIA: (2) (‘666) VASCULAR DISEASE (‘511)
CELUTION DEVICE (‘135) MEXICO: (1)
MEXICO: (1)
STEMSOURCE DEVICE (‘901) CELUTION FOR RESTORING BLOOD FLOW
CELUTION & FUTURE INDIA: (1)
GENERATIONS (‘348) (‘775) ADRCS FOR WOUND
CHINA: (1)
CELUTION DEVICE (‘689) HEALING (‘580)
ISRAEL: (1)
KOREA: (1) ADRCS FOR CARDIAC (‘354)
CELUTION WITH CENTRIFUGE
OR FILTER (‘305) CANADA: (1)
ADRCS FOR RESTORING BLOOD
FLOW(‘510)
8
JAPAN: (1)
CELUTION FOR RESTORING BLOOD
FLOW(‘787)

9. i. Business and Technology Overview
ii. Cardiovascular Pipeline
iii. Soft Tissue Pipeline
iv. Commercial
CYTORI CELL THERAPY
9

10. Refractory Heart Failure
Condition: Severe form of coronary artery disease due to chronic
myocardial ischemia and leads to death
Disease Course: Declining cardiac function leads to heart
transplantation or death
Size of Market: Approx.120K to 250K diagnosed each year in U.S.
(subset of approx. 5.8 MM heart failure patients)
Cytori Cell Therapy: Potential to revive living but stressed heart
tissue; Halt progressive disease & keep patient off transplant list;
overcome limits of existing drugs, devices and surgical options
10

11. 28 Month Mortality Rate
PRECISE Trial
Treated
Placebo
0% 50%
20.0
19.0
P<0.05 P<0.02
18.0
VO2Max
17.2 17.1
ADRC’s
16.6 Increased
16.0 Mortality
15.5 Standard of Care
15.3
14.0 Transplant List
Baseline 6 Mos 18 Mos
Change in Peak Oxygen Consumption (VO2Max) from Baseline to 6 & 18 months 11
N=27; 21 active, 6 control

12. U.S. Refractory Heart Failure Trial
• Device-based PMA/IDE study
• Multi-center, prospective, randomized, double-blind, blinded core labs
• Up to 45 patients with 2:1 randomization at six sites
- Texas Heart, Minneapolis Heart, USF, Scripps, Alabama, U. Florida
• Dose: 0.4 million cells/kg body weight
• Endpoints:
- Clinical Safety through 12 months
- Peak oxygen consumption (VO2 Max) at 6 months
- Perfusion defect at 6 months
- Left ventricle end-systolic and diastolic volume at 6 months
- Ejection fraction at 6 months
- Re-hospitalization, heart failure symptoms & quality of life @ 12 mo
• Enrollment initiated Sept 2012 / complete enrollment by mid-2013
12

13. Acute Myocardial Infarction
Condition: Artery blockage inhibits blood flow to heart muscle
resulting in left ventricular damage
Disease Course: More damage to the heart correlates to a higher
rate of progression toward heart failure
Size of Market: Approx.1 million heart attack patients admitted to
hospital each year, 38% are STeMI’s
Cytori Cell Therapy: Minimize heart damage and reduce rate to
progressive disease; additive to existing treatments; potential to
reduce healthcare costs & re-hospitalizations linked to heart failure
(leading healthcare cost in US & leading cause of death globally)
13

14. APOLLO: EU AMI Pilot Trial
Potential new approach for treatment of heart attacks
 Safe & feasible
 Strong trends in favor of efficacy: improvement in perfusion, reduced infarct size
 Less remodeling toward heart failure at 18 months
35%
32%
46% of patients
30%
Progress to
% Left Placebo
25% 25% Heart Failure
Ventricle 25%
infarct size
20%
15% 7% of patients
ADRC 15% Progress to
P < 0.05 for change
10%
from BL for ADRCs Heart Failure
5%
Baseline 6 Months 14

15. ADVANCE: EU AMI Approval Trial
• Device-based trial predominately in EU - G6 & Canada
• Multi-center, prospective, randomized, double-blind
• Up to 216 patients with 2:1 randomization at up to 35 sites
• Dose: 20 million ADRCs (or placebo) delivered intracoronary
• Endpoints:
- Primary
o Reduction of Infarct size at six months (MRI)
- Secondary
o Clinical endpoints of MACCE, improvement in perfusion (SPECT)
o Additional assessments in LVEF, Volumes, Holter monitoring for
ventricular arrhythmias, & quality of life
• Trial enrollment resumed in the 4th quarter of 2012
• 10-15 trial sites selected and committed
• Multiple patients have been enrolled under new protocol
15

16. i. Business and Technology Overview
ii. Cardiovascular Pipeline
iii. Soft Tissue Pipeline
iv. Commercial
CYTORI CELL THERAPY

17. Thermal Burns: Up to $106 Million from BARDA
U.S. Govt. contract: Thermal burns combined with radiation injury
• National preparedness to counter radiological bomb
• Funds complete development: preclinical to FDA submission
• New soft tissue pipeline application in U.S.
• Procurement potential above and beyond contract
Options 1 & 2
• $4.7 MM in funding • Up to $45 MM
• Preclinical model • Pivotal trial
• Up to $55 MM
• Next-Gen Celution® • FDA submission
• Development
development
including clinical
• Up to 2 years
• Govt. has
Proof-of- procurement ability Option 3
Concept
17

18. Burn & Radiation Injury Clinical Experience
90% cells to circular area around sore
Exposed Sacrum
Note sig. inflammation, redness, swelling 10% cells to sore itself
Immediate Pre Op Intra Op, Debrided Intra Op, Post-Cell Rx 1 Year Post Op
Chronic burn injury: Pre-Op Chronic burn injury: Post-Op 18-mo
18

19. i. Business and Technology Overview
ii. Cardiovascular Pipeline
iii. Soft Tissue Pipeline
iv. Commercial
CYTORI CELL THERAPY

20. Expanding Claims,
Accelerating Revenue Growth
2012 Revenue Target of $9 Million
 Target exceeded based on products shipped (pending auditor review of revenue)
Class I Device Clearance in Japan
 Facilitates system & bank sales
 Academic customers performing investigator-led studies
 Shipments under new approval began in late Q3 2012
 Cell cryopreservation & tissue banking
CE Mark Expansion
 New soft tissue indications in Q3 2012: fistula, sports injury, tissue ischemia
 EU Vascular delivery indication pending
2013 Revenue Expectations
• Continue to delivery year over year revenue growth
20

21. Financials
Cash & Accts Receivable (Q3 2012) $20 MM
Public offering (Dec 2012) $20 MM
Senior Term Loan (GE) $25 MM
Shares outstanding 65 MM
Multiple partnership opportunities under negotiation
21

22. Milestones
2012 Milestones Achieved
Published APOLLO primary endpoints (6-months) √
Published RESTORE 2 12-month results √
Partnership with BARDA (contract for up to $106 mm) √
Initiated patient enrollment in ATHENA √
Re-initiated ADVANCE enrollment √
Expanded Claims in EU & Class 1 Approval in Japan √
Achieve $9 million revenue target for 2012 pending
2013 Milestones
CE Mark expansion for intravascular use
Complete enrollment in ATHENA
Complete the Proof of Concept Phase of BARDA contract
Significant revenue growth, reduce cash op loss
Publish PRECISE outcomes

23. CYTORI
Personalized Cell Therapy
THE TRUSTED LEADER
IN CELL THERAPY